Skip to main content
Top
Published in: BMC Gastroenterology 1/2019

Open Access 01-12-2019 | Computed Tomography | Case report

Endoscopic resection of giant gastrointestinal stromal tumor at the esophagogastric junction: a case report

Authors: Feng Xue, Wei Wang, Ning Shi, Xing-Bin Ma, Cheng-Xia Liu

Published in: BMC Gastroenterology | Issue 1/2019

Login to get access

Abstract

Background

Gastrointestinal stromal tumors (GISTs) at the esophagogastric junction are rare and its treatment is complicated and challenging. Endoscopic resection has advantages with less complications compared to open and laparoscopic surgery.

Case presentation

We report a 33-year-old male patient who was admitted to our department complaining of abdominal fullness for 20 days. A huge submucosal tumor at the esophagogastric junction was found by upper gastrointestinal endoscopy. We successfully resected the lesion through endoscopic submucosal excavation without complications, which was pathologically confirmed to be a GIST. The patient was discharged 5 days after operation and has been doing well, and there was no recurrence 8 months after the operation.

Conclusion

ESE is possibly an effective and minimally invasive method of giant esophagogastric junction stromal tumor.
Literature
1.
go back to reference Joensuu H, Kindblom LG. Gastrointestinal stromal tumors--a review. Acta Orthop Scand Suppl. 2004;75(311):62–71.CrossRef Joensuu H, Kindblom LG. Gastrointestinal stromal tumors--a review. Acta Orthop Scand Suppl. 2004;75(311):62–71.CrossRef
2.
go back to reference Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.CrossRef Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.CrossRef
3.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.CrossRef Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.CrossRef
4.
go back to reference Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, He Y, Liang X, Liu X, Zhou Y. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chinese J Cancer Res. 2017;29(4):281–93.CrossRef Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, He Y, Liang X, Liu X, Zhou Y. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chinese J Cancer Res. 2017;29(4):281–93.CrossRef
5.
go back to reference Walsh RM, Heniford BT. Laparoendoscopic treatment of gastric stromal tumors. Semin Laparosc Surg. 2001;8(3):189–94.CrossRef Walsh RM, Heniford BT. Laparoendoscopic treatment of gastric stromal tumors. Semin Laparosc Surg. 2001;8(3):189–94.CrossRef
6.
go back to reference Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.CrossRef Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.CrossRef
Metadata
Title
Endoscopic resection of giant gastrointestinal stromal tumor at the esophagogastric junction: a case report
Authors
Feng Xue
Wei Wang
Ning Shi
Xing-Bin Ma
Cheng-Xia Liu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2019
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-019-1151-5

Other articles of this Issue 1/2019

BMC Gastroenterology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.